Welcome to our dedicated page for Scpharmaceutical news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on Scpharmaceutical stock.
scPharmaceuticals Inc. (formerly traded on Nasdaq under the symbol SCPH) generated a steady stream of company-specific news before and during its acquisition by MannKind Corporation. Public announcements and SEC filings show that scPharmaceuticals focused on cardiorenal healthcare, with news often centered on FUROSCIX, a subcutaneous furosemide injection indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome.
News coverage for scPharmaceuticals has included product and clinical updates, such as FDA approval of an expanded FUROSCIX indication to include chronic kidney disease and the formal launch of FUROSCIX into that market. The company also reported progress on its SCP-111 furosemide formulation and related autoinjector program, including multiple Notices of Allowance from the U.S. Patent and Trademark Office for patents covering SCP-111 and plans for supplemental NDA submissions.
Financial and corporate updates have been another major theme. scPharmaceuticals regularly issued press releases on quarterly and annual financial results, highlighting net FUROSCIX revenues, dose volumes, prescriber adoption, and expansion into integrated delivery networks. Additional news detailed participation in investor conferences, financing arrangements, and credit facilities.
A key set of news items in 2025 described MannKind’s agreement to acquire scPharmaceuticals, the tender offer terms, and the strategic rationale around cardiorenal and cardiometabolic care. Subsequent releases and a Form 8-K dated October 7, 2025 confirmed completion of the tender offer and merger, after which scPharmaceuticals became a wholly owned subsidiary of MannKind and its shares were delisted from Nasdaq. This news page therefore serves as an archive of historical announcements, from product and regulatory milestones to the transaction that ended SCPH’s life as an independent public stock.
MannKind (Nasdaq: MNKD) completed its acquisition of scPharmaceuticals (SCPH) on October 7, 2025, creating a cardiometabolic-focused commercial platform that combines Afrezza, FUROSCIX, V-Go and Tyvaso DPI‑related revenues.
The company cited an annualized revenue run rate of over $370 million based on Q2 2025 results. The deal paid $5.35 per scPharmaceutical share in cash plus one non-tradable contingent value right (CVR) per share for up to an additional $1.00 in milestone cash, for total consideration of up to $6.35 per share. The FUROSCIX ReadyFlow Autoinjector sNDA was submitted in Q3 2025. Following the merger, scPharmaceuticals became a wholly owned MannKind subsidiary and SCPH common stock ceased trading on Nasdaq as of the close.
MannKind Corporation (Nasdaq: MNKD) has announced the acquisition of scPharmaceuticals (Nasdaq: SCPH) in a deal valued up to $360 million. The transaction includes an upfront payment of $5.35 per share plus a CVR worth up to $1.00 per share, representing a 36% premium to SCPH's 90-day VWAP.
The acquisition brings FUROSCIX®, an FDA-approved treatment for fluid overload in chronic heart failure and chronic kidney disease patients, with a $10+ billion U.S. market opportunity. FUROSCIX achieved strong H1 2025 performance with net sales of $27.8 million, up 96% year-over-year. The combined company projects an annualized revenue run rate of over $370 million based on Q2 2025 results.
The deal is expected to close in Q4 2025, strengthening MannKind's position in cardiometabolic and lung diseases while accelerating double-digit revenue growth through multiple commercial assets including Afrezza®, FUROSCIX, and V-Go®.
scPharmaceuticals (NASDAQ: SCPH) has received five Notices of Allowance from the USPTO for patent applications covering their latest furosemide formulation, SCP-111. These patents will join four existing patents owned by the company for the same formulation.
The company plans to file a supplemental New Drug Application (NDA) for SCP-111 in the current quarter. The expanded patent protection strengthens SCPH's intellectual property portfolio for treating edema in patients with heart failure or chronic kidney disease.
scPharmaceuticals (NASDAQ:SCPH) reported strong Q2 2025 financial results, with FUROSCIX® generating $16 million in net revenue, representing a 99% increase year-over-year. The company achieved significant growth with 20,200 FUROSCIX doses filled, up 117% from Q2 2024.
Key highlights include the successful launch of FUROSCIX for chronic kidney disease (CKD) treatment in April 2025, and the upcoming sNDA submission for the 80mg/1mL FUROSCIX Autoinjector in Q3 2025, which aims to reduce treatment time from five hours to under ten seconds. The company maintained a strong financial position with $40.8 million in cash as of June 30, 2025.
Despite revenue growth, the company reported a net loss of $18.0 million for Q2 2025, compared to $17.1 million in Q2 2024, with increased operating expenses across R&D and SG&A.
scPharmaceuticals (NASDAQ: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the quarterly results and provide business updates.
Interested participants can join via phone using the toll-free number (800) 715-9871 or toll number (646) 307-1963 with passcode 4965353. The webcast will be available through the company's Investor Relations section on their website.
scPharmaceuticals (NASDAQ: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has scheduled its Q1 2025 financial results announcement for May 14, 2025, after market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the quarterly results and provide a business update. Interested participants can access the call through a direct registration link, while the webcast and its replay will be available on the company's website under the Investor Relations section.
scPharmaceuticals Inc. (SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has announced its participation in three upcoming investor conferences in May 2025. CEO John Tucker will present at:
- The Citizens Life Sciences Conference on May 7 at 9:30 a.m. ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20 at 10:00 a.m. ET
- Craig-Hallum 22nd Annual Institutional Investor Conference on May 28 (investor meetings only)
Webcasts of the presentations will be available on the company's website under the Investor Relations section.
scPharmaceuticals (SCPH) reported strong Q4 and full-year 2024 results, with Q4 FUROSCIX revenue reaching $12.2 million (up 99% YoY) and full-year revenue of $36.3 million (up 167% YoY). The company filled approximately 13,300 FUROSCIX doses in Q4 2024, a 23% increase from Q3.
Key highlights include FDA approval for FUROSCIX's expanded label to treat edema in chronic kidney disease patients, with launch planned for April 2025. The company reported about 3,800 unique prescribers through year-end 2024, showing 23% growth from Q3. The gross-to-net discount was 19% for Q4 and 16% for full-year 2024.
Financial position remains strong with $75.7 million in cash and cash equivalents as of December 31, 2024. However, the company reported a net loss of $18.8 million in Q4 and $85.1 million for the full year 2024.
scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has scheduled its Fourth Quarter and Full Year 2024 Financial Results announcement for Wednesday, March 19, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET following market close.
Management will present financial results and provide a business update during the call. Investors and interested parties can access the event through a direct registration link, with both live webcast and replay options available on the company's website under the Investor Relations section.